Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Transcriptomics Market, by Technology
1.4.2 Europe Transcriptomics Market, by Application
1.4.3 Europe Transcriptomics Market, by Component
1.4.4 Europe Transcriptomics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2017-2021)
3.3.2 Key Strategic Move: (Acquisitions and Mergers: 2019, Jan – 2021, Apr) Leading Players
3.3.3 Key Strategic Move: (Product Launches ad Product Expansions: 2018, Mar – 2021, Nov) Leading Players
Chapter 4. Europe Transcriptomics Market by Technology
4.1 Europe q PCR Market by Country
4.2 Europe Microarrays Market by Country
4.3 Europe Sequencing Technology Market by Country
Chapter 5. Europe Transcriptomics Market by Application
5.1 Europe Drug Discovery Market by Country
5.2 Europe Diagnostics & Disease Profiling Market by Country
5.3 Europe Others Market by Country
Chapter 6. Europe Transcriptomics Market by Component
6.1 Europe Consumables Market by Country
6.2 Europe Instruments Market by Country
6.3 Europe Software Market by Country
6.4 Europe Services Market by Country
Chapter 7. Europe Transcriptomics Market by Country
7.1 Germany Transcriptomics Market
7.1.1 Germany Transcriptomics Market by Technology
7.1.2 Germany Transcriptomics Market by Application
7.1.3 Germany Transcriptomics Market by Component
7.2 UK Transcriptomics Market
7.2.1 UK Transcriptomics Market by Technology
7.2.2 UK Transcriptomics Market by Application
7.2.3 UK Transcriptomics Market by Component
7.3 France Transcriptomics Market
7.3.1 France Transcriptomics Market by Technology
7.3.2 France Transcriptomics Market by Application
7.3.3 France Transcriptomics Market by Component
7.4 Russia Transcriptomics Market
7.4.1 Russia Transcriptomics Market by Technology
7.4.2 Russia Transcriptomics Market by Application
7.4.3 Russia Transcriptomics Market by Component
7.5 Spain Transcriptomics Market
7.5.1 Spain Transcriptomics Market by Technology
7.5.2 Spain Transcriptomics Market by Application
7.5.3 Spain Transcriptomics Market by Component
7.6 Italy Transcriptomics Market
7.6.1 Italy Transcriptomics Market by Technology
7.6.2 Italy Transcriptomics Market by Application
7.6.3 Italy Transcriptomics Market by Component
7.7 Rest of Europe Transcriptomics Market
7.7.1 Rest of Europe Transcriptomics Market by Technology
7.7.2 Rest of Europe Transcriptomics Market by Application
7.7.3 Rest of Europe Transcriptomics Market by Component
Chapter 8. Company Profiles
8.1 Fluidigm Corporation
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent strategies and developments:
8.1.5.1 Product Launches and Product Expansions:
8.2 Promega Corporation
8.2.1 Company Overview
8.3 General Electric (GE) Co. (GE Healthcare)
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expense
8.4 Merck & Co., Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expenses
8.5 Thermo Fisher Scientific, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 Recent strategies and developments:
8.5.5.1 Acquisition and Mergers:
8.5.6 SWOT Analysis
8.6 Illumina, Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.7 Bio-Rad laboratories, Inc.
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expenses
8.7.5 Recent strategies and developments:
8.7.5.1 Partnerships, Collaborations, and Agreements:
8.7.5.2 Product Launches and Product Expansions:
8.7.5.3 Acquisition and Mergers:
8.8 Agilent Technologies, Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expense
8.8.5 Recent strategies and developments:
8.8.5.1 Acquisition and Mergers:
8.9 F. Hoffmann-La Roche Ltd.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental and Regional Analysis
8.9.4 Research & Development Expense
8.10. Qiagen N.V.
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional Analysis
8.10.4 Research & Development Expense
8.10.5 Recent strategies and developments:
8.10.5.1 Partnerships, Collaborations, and Agreements:
8.10.5.2 Product Launches and Product Expansions:
8.10.5.3 Acquisition and Mergers:
Unique Offerings 
